Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt.
They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. The shares closed at $72.57 on September 24, which is 43 cents below what the buyer has agreed to pay.
READ ALSO: 10 Best Life Sciences Stocks to Buy According to Hedge Funds
A Cleared Antitrust Path Puts the Deal Within Months of Closing:
Bio-Techne makes the reagents, proteins, and antibodies used in laboratories, the consumable supplies that researchers buy repeatedly rather than once. It is an unglamorous corner of life sciences with attractive economics, because the customer keeps coming back. Research budgets move slowly, but they rarely stop, and a laboratory that has validated a supplier does not casually switch.
That is what Merck KGaA is buying. The German group has been assembling a life sciences business for years, and reagents fit alongside what it already sells to the same laboratories.
The regulatory path is largely clear. The antitrust waiting period in the United States expired on September 18, which removes the hurdle that most often delays a transaction of this kind.
Bio-Techne expects the deal to complete in late 2026 or early 2027, subject to the remaining approvals. With the shareholder vote behind it, the outcome now rests with regulators rather than owners.
DON’T MISS: Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades
The Rejected Pay Vote is the More Interesting Result:
Approving a takeover while rejecting the pay package attached to it is a pointed combination. Shareholders wanted the sale. They did not want to fund the arrangements management negotiated alongside it.
That vote is advisory rather than binding, so the payments proceed regardless. Its value is as a signal, and the signal is that owners felt the split between what they receive and what executives receive was wrong.
Deals at this stage rarely fail, though they do stall. The approvals still outstanding sit outside the United States, and those timetables are not the company’s to set.
For anyone still holding the shares, the practical question now is time rather than price. A deal that closes in late 2026 or early 2027 leaves months during which the money is committed and doing nothing else.
There is a residual risk too. Remaining regulatory approvals are usually a formality, but a cross-border transaction between a German acquirer and an American target has more places to get stuck than a domestic one.
The 43-cent gap to the offer price is the whole opportunity now. Buying at $72.57 to receive $73 is a return of about half a percent, and there is a long way to fall if the deal does not happen. That is the ordinary arithmetic of owning a company that has already agreed to be bought.
Conclusion:
Bio-Techne shareholders have cleared the path for Merck KGaA to buy the company. With the United States antitrust waiting period already expired, the transaction looks likely to complete in late 2026 or early 2027. The rejected compensation vote will not change the payments, but it records what owners thought of them. The date to watch is the remaining regulatory clearance. Until then, the shares are a bet on a closing schedule rather than on a laboratory supplies business.
Market Sentiment:
Bio-Techne Corporation was held by 63 hedge funds with a combined stake value of about $1.8 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 41 hedge fund holders with a cumulative investment value of around $1.0 billion in the previous quarter.
READ NEXT: Visa (V) vs American Express (AXP): Which is a Better Stock to Buy and Twilio (TWLO) Keeps Climbing as Investors Rediscover its AI Business
This article is originally published at Insider Monkey.
